Carta Healthcare Acquires Realyze Intelligence to Enhance AI-Powered Oncology Research
核心洞察
Carta Healthcare (搜索) acquired Realyze Intelligence (搜索) to enhance its AI-powered platform for clinical data analysis, particularly in oncology.
Realyze Intelligence (搜索)'s AI rapidly analyzes EHR data to match cancer (搜索) patients with clinical trials, reducing the time from hours to seconds.
The integration aims to improve patient outcomes by accelerating clinical trial enrollment and optimizing care pathways through better data utilization.
Carta Healthcare (搜索) has expanded its AI-powered platform through the acquisition of Realyze Intelligence (搜索), a UPMC Enterprises company. The acquisition aims to accelerate oncology research and clinical trials by leveraging AI to efficiently match patients with suitable studies. This combination seeks to address the urgent need for faster, more accurate data analysis in the face of rising cancer (搜索) rates and the complexities of clinical trial enrollment.
AI-Driven Patient Matching
Realyze Intelligence (搜索)'s technology uses clinician-trained AI to analyze structured and unstructured data within electronic health records (EHRs). This enables the rapid identification of ideal patients for clinical trials, reducing the time required for cohort assembly from hours to seconds. According to Realyze Intelligence, UPMC Hillman Cancer (搜索) Center saw a sevenfold increase in patient matches to trials and a doubling of enrollment using the software, compared to manual methods.
Addressing Clinical Trial Enrollment Challenges
Currently, only 7% of cancer (搜索) patients participate in clinical trials, despite a reported 50% willingness to enroll if recruited. A significant barrier is the manual extraction and review of unstructured patient notes, which contain over 80% of trial inclusion and exclusion criteria. Carta Healthcare (搜索)'s enhanced platform aims to overcome this obstacle by automating data abstraction for cancer and other clinical data registries, with expert clinician oversight.
Integration Benefits and Future Impact
The integration of Realyze Intelligence (搜索)'s AI with Carta Healthcare (搜索)'s platform promises to significantly reduce the time and costs associated with data abstraction for clinical data registries, research, and internal clinical quality performance programs in oncology, cardiovascular health, and other specialties. The combined technologies offer faster insights and reduced labor demands, which is crucial as cancer (搜索) is poised to overtake cardiovascular disease (搜索) as the leading cause of death worldwide.
"We believe data is the single most important ingredient to improve healthcare," said Brent Dover, CEO of Carta Healthcare (搜索). Aaron Brauser, founder and CEO of Realyze Intelligence (搜索), added, "We are excited to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways and improve patient outcomes with Carta Healthcare."